DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




More Industry Headlines

New VR app may ease MR anxiety Hope to cut down on the need to sedate patients

Scalable AI utilization insights from Montefiore at RSNA Starting with patients at risk for respiratory failure

NYU releases biggest ever MR data set in AI Facebook collaboration With fastMRI, acceleration of imaging by factor of four 'already possible'

Ramsoft partners with QliqSOFT Enables secure messaging of information on mobiles among doctors and patients

Hitachi unveils new CT scanner, Scenaria View 128, at RSNA Provides better workflow with SynergyDrive and large, 80 cm aperture

GE and VA partner to build 3D printing network Holds promise for reducing surgery imaging preparation time

DiA showcases AI solution for point-⁠of-⁠care cardiac ultrasound 'Game changer' technology now available with Vscan Extend from GE Healthcare

Spectrum Dynamics files lawsuit against GE Alleges theft of intellectual property regarding VERITON-CT

Elekta Unity MR-linac gains FDA 510(k) clearance Simultaneously delivers radiation dose and visualization of tumors

Subtle Medical closes RSNA with CE mark and FDA clearance of PET AI solution Speeds up scans by factor of four, enhanced image quality

Dr. Robert Zivadinov

New biomarker could be a game changer for multiple sclerosis research, study

by Loren Bonner , DOTmed News Online Editor
A new study could give multiple sclerosis researchers more insight into the disease and potentially offer clinicians a better way to treat patients with MS.

Most doctors evaluate MS by examining MRI scans of new gadolinium-enhanced lesions on patients after an initial attack. But over the past few years, MS research has focused on an area deep within the brain called the thalamus. As more studies surface, MRI measurements of thalamic atrophy are being viewed as an improvement over the current evaluation method.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

This new study is one of them. Published online in the journal Radiology, the study is the first to examine thalamic volume in patients longitudinally. It looked at both the appearance of new lesions and the loss of thalamic volume over a two year period. Decreases in thalamic volume and an increase in lateral ventricle volumes were the only MRI measures independently associated with the development of clinically definite MS, according to the study.

"We found that the deterioration of the thalamus was actually more predictive for the second clinical attack than the appearance of gadolinium-enhanced lesions," Dr. Robert Zivadinov from the Buffalo Neuroimaging Analysis Center of the University at Buffalo in Buffalo, N.Y, told DOTmed News. "This is an important finding because it's telling you that actually we should be open to looking at other markers of the disease."

Zivadinov said translating his results for the clinical space is still one big hurdle since radiologists can't volumetrically measure thalamus on a scan. However, one answer might come in looking at the enlargement of the third ventricle — an indirect sign of thalamic atrophy.

MS develops as the body's immune system attacks and damages myelin, the protective layer of fatty tissue that surrounds nerve cells within the brain and spinal cord. Symptoms include visual disturbances, muscle weakness and trouble with coordination and balance.

Zivadinov considers his study a breakthrough for establishing a new MS biomarker, which can also influence the way new drugs are developed to treat MS. Thalamic atrophy, also an ideal MRI biomarker because it's detectable at a very early stage of the disease.

"I would say the value of this study in radiology is really using this as a biomarker. I think that all future trials that are investigating the effects of therapy should use thalamic atrophy as the principle neurodegenerative biomarker," said Zivadinov.

Currently, there is no cure for MS, but early diagnosis and treatment can slow development of the disease.

Back to HCB News
  Pages: 1


You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.